These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21736869)

  • 21. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
    de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
    J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
    Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
    Mehdizadeh M; Parkhideh S; Salari S; Hajifathali A; Rezvani H; Mabani M
    Asian Pac J Cancer Prev; 2021 May; 22(5):1639-1644. PubMed ID: 34048196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
    O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
    Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
    Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
    Kerbauy FR; Rodrigues M; de Souza Santos FP; Sobrinho JN; Kutner JM; Torres MA; Ribeiro AA; de Lima M; Hamerschlak N
    Leuk Lymphoma; 2011 Feb; 52(2):321-4. PubMed ID: 21281240
    [No Abstract]   [Full Text] [Related]  

  • 30. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Clemmons AB; Evans S; DeRemer DL; Awan FT
    J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan.
    Iemura T; Kondo T; Ueda A; Maeda T; Kitawaki T; Arai Y; Kanda J; Ikeda T; Imada K; Ishikawa T; Anzai N; Itoh M; Takeoka T; Akasaka T; Yago K; Yonezawa A; Arima N; Kitano T; Nohgawa M; Watanabe M; Moriguchi T; Yamashita K; Ueda Y; Matsumoto K; Takaori-Kondo A
    Ann Hematol; 2023 Oct; 102(10):2909-2922. PubMed ID: 37052663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
    Freytes CO; Toro JJ; Yeh RF; Stadtmauer EA; Ratanatharathorn V; Akpek G; Sahovic E; Tricot GJ; Shaughnessy PJ; White DJ; Rodriguez TE; Solomon SR; Yu LH; Zhao C; Patil S; Armstrong E; Smith A; Elekes A; Kato K; Reece DE
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1949-57. PubMed ID: 25139216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.